Baltimore-based Cerecor has gathered up the first half of a $33 million B round, with plans to devote much of that money to a midstage development program for an experimental depression therapy recently punted by a restructuring Merck.
The Wall Street Journal said that the drugmaker plans to test Zilmax in about 250,000 cattle in a randomized, controlled study. But sources say beef producers like Cargill and JBS SA have pushed back against the move. While Merck planned to have the feed additive on the market by this summer, the study has been delayed.
Merck wants to get its cattle feed additive Zilmax back to multimillion-dollar sales. But with lingering reservations from beef producers and sellers, that may be easier said than done--and competition is ramping up in the meantime.
Third Rock Ventures partner Cary Pfeffer is stepping aside as the start-up CEO at Jounce Therapeutics in favor of Merck veteran Richard Murray.
Worries over Gardasil's safety are just one of the issues that have hampered uptake of Merck's best-selling vaccine for HPV. But now, a study published in JAMA says patients need not worry about an increased risk of deadly blood clots.
Best-selling drugs did well for themselves in 2013, churning out more than $76 billion in sales. But big-name brands could stand the test of time and help the top 10 rake in more than $80 billion in 2020, according to a new report.
Doctor education is not a new way for pharma companies to make a name for themselves in emerging countries where methods like DTC advertising won't do the trick. But Merck has put its own spin on that doctor education with its online portal, and now it's bringing the service to India.
As the FDA continues its effort to phase out antimicrobials, the numbers aren't looking so good for the contracting market.
In February and again in May, Merck sent a cease-and-desist order to Alberto Donzelli, head of education, appropriateness, and evidence-based medicine at Milan's public health authority. Donzelli had openly criticized Merck's cholesterol-lowering drug Ezetrol (ezetimibe), which is sold in the U.S. as Zetia. Now the company is doing an about-face.
Investors in migraine device startup electroCore has expanded its Series A round to $50 million. The company initially secured a $40 million tranched round in March 2013. The newly expanded financing comes just as the company prepares to submit its product to the FDA.